INT230-6 demonstrated a systemic increase in the median diversity of T-cell repertoire in patients blood compared to baseline that was also much larger than a.
/PRNewswire/ Intensity Therapeutics, Inc. ("Intensity" or the "Company") (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and.
/PRNewswire/ Intensity Therapeutics, Inc. (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary,.
Webcast to be Held at 8:00 am ET on Monday, August 14, 2023
WESTPORT, Conn., Aug. 7, 2023 /PRNewswire/ Intensity Therapeutics, Inc. , a clinical-stage biotechnology company focused on the.
WESTPORT, Conn., July 10, 2023 /PRNewswire/ Intensity Therapeutics, Inc. , a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based.